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Abstract
Many published studies reflect the growing application of complementary and alternative medicine, particularly Chinese
herbal medicine (CHM) use in combination with conventional cancer therapy for advanced non-small cell lung cancer
(NSCLC), but its efficacy remains largely unexplored. The purpose of this study is to evaluate the efficacy of CHM combined
with conventional chemotherapy (CT) in the treatment of advanced NSCLC. Publications in 11 electronic databases were
extensively searched, and 24 trials were included for analysis. A sum of 2,109 patients was enrolled in these studies, at which
1,064 patients participated in CT combined CHM and 1,039 in CT (six patients dropped out and were not reported the group
enrolled). Compared to using CT alone, CHM combined with CT significantly increase one-year survival rate (RR = 1.36, 95%
CI = 1.15–1.60, p = 0.0003). Besides, the combined therapy significantly increased immediate tumor response (RR = 1.36, 95%
CI = 1.19–1.56, p,1.0E25) and improved Karnofsky performance score (KPS) (RR = 2.90, 95% CI = 1.62–5.18, p = 0.0003).
Combined therapy remarkably reduced the nausea and vomiting at toxicity grade of III–IV (RR = 0.24, 95% CI = 0.12–0.50,
p = 0.0001) and prevented the decline of hemoglobin and platelet in patients under CT at toxicity grade of I–IV (RR = 0.64,
95% CI = 0.51–0.80, p,0.0001). Moreover, the herbs that are frequently used in NSCLC patients were identified. This
systematic review suggests that CHM as an adjuvant therapy can reduce CT toxicity, prolong survival rate, enhance
immediate tumor response, and improve KPS in advanced NSCLC patients. However, due to the lack of large-scale
randomized clinical trials in the included studies, further larger scale trials are needed.
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Introduction
Lung cancer is the most common malignancy worldwide and a
leading cause of cancer-related deaths. In 2012, it is estimated that
160,300 deaths (87,700 in men, 72,600 in women) from lung
cancer would occur in the United States [1].
The non-small cell lung cancer (NSCLC) is the most common
form of lung cancer, which accounts for approximately 85% of all
lung cancer cases. Nowadays the standard treatment for patient
with advanced NSCLC who has a good performance status,
platinum-based chemotherapy (CT) is the first-line regimen [2,3].
However, platinum-based CT has the potential for severe adverse
events, and the International Adjuvant Lung Cancer Trial suggests
that more deaths in the CT group and the benefit of CT decreased
over time [4,5]. In spite of the development of new CT regimens
use in the treatment of NSCLC, the prognosis of the patients
remains poor. Its five-year survival rate is as low as 15.9% [6,7].
Thus, there is an increasing awareness to maximize tumor control,
prolong overall survival, minimize CT side-effects and improve
quality of life (QoL).
In complementary and alternative medicine (CAM), Chinese
herbal medicine (CHM) has become increasingly popular for the
patients with advanced NSCLC. Recent studies have reported
some CHMs in associated with platinum-based CT have definite
superiority in relieving the symptoms of lung cancer patients,
reducing the severe adverse effects (AEs) of standard cancer
therapy, enhancing short-term efficacy and improving patients
QoL [8]. There are a variety of herbs being used in different
combinations and forms, such as oral administration and
intravenous injection, to treat advanced NSCLC combined with
platinum-based CT. However, albeit a number of studies being
published in Chinese, the evidence on efficacy of CHM as
adjuvant therapy to conventional CT is not well demonstrated in
the Western world. Thus, the aim of this study is to carry out a
comprehensive systematic review about the efficacy of CHM as an
adjunctive therapy for advanced NSCLC.
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Figure 1. Flow chart of study selection.
doi:10.1371/journal.pone.0057604.g001
Figure 2. Number of patients with survival .one-year. Overall survivals estimated from meta-analysis of pairwise comparisons in the patients
with chemotherapy combined Chinese herbal medicine (CTC, treatment group) versus patients in chemotherapy (CT, control group).
doi:10.1371/journal.pone.0057604.g002
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Methods
Clinical trials were retrieved from 11 databases as well as from
conference papers and theses. The studies were reviewed
independently by SGL and HYC. The data from included studies
were extracted by the first reviewer and verified by the second
reviewer. Discrepancies were rectified referring to the original
articles. Only the studies which satisfied the criteria were included
in the meta-analysis.
Search Strategy
The terms retrieved in databases were as the following: (non-
small-cell lung cancer OR non-small-cell lung carcinoma OR
NSCLC OR squamous cell lung carcinoma large cell lung
carcinoma OR lung adenocarcinoma) AND (Chinese medicine
OR traditional Chinese medicine OR Chinese herbal medicine
OR Chinese herbal drug OR traditional herbal medicine OR
herbal medicine OR traditional Japanese medicine OR traditional
medicine OR ethnomedicine OR folk medicine OR folk remedies
OR home remedies OR indigenous medicine OR primitive
medicine OR materia medica OR homeopathic remedies OR
nosodes OR traditional East Asian medicine OR traditional Far
Eastern medicine OR Far East medicine OR Oriental medicine
OR Korean medicine OR Tibetan medicine OR herb OR
herbaceous agent OR medicinal plant OR medicinal herbs OR
medicinal plant product OR plant extract OR plant preparation
OR herbal preparation OR botanic OR botany OR Kampo OR
Kanpo OR traditional Mongolian medicine OR Mongolian folk
Figure 3. Immediate tumor responses. Immediate tumor responses estimated from meta-analysis of pairwise comparisons in patients with
chemotherapy combined Chinese herbal medicine (CTC, treatment group) versus patients in chemotherapy (CT, control group).
doi:10.1371/journal.pone.0057604.g003
Figure 4. Quality of life. The quality of life changes on Karnofsky performance scale (KPS) were estimated from meta-analysis of pairwise
comparisons in patients with Chinese herbal medicine (CTC, treatment group) versus patients in chemotherapy (CT, control group). KPS improvement
(the increase of KPS $10).
doi:10.1371/journal.pone.0057604.g004
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medicine OR Mongolian medicine OR phytotherapy OR herb
therapy OR herbal therapy OR ethnopharmacology OR ethno-
botany OR phytogenic OR alternative medicine OR alternative
therapy OR complementary therapy OR complementary medi-
cine OR TCM OR CHM OR Zhong Yi Xue) AND (clinical trial
OR randomized controlled trial OR controlled clinical trial OR
multicenter study OR phase 1 clinical trial OR phase 2 clinical
trial OR phase 3 clinical trial OR phase 4 clinical trial). The terms
in Chinese adopted from the above terms were retrieved in
Chinese databases.
Databases
The databases in English language included EMBASE (1974 to
September 2012), MEDLINE (1946 to September 2012), AMED
(from 1985 to September 2012), EBM Reviews included Cochrane
Database of Systematic Reviews (2005 to September 2012), ACP
Journal Club (1991 to September 2012), Database of Abstracts of
Reviews of Effects (September 2012), Cochrane Central Register
of Controlled Trials (September 2012), Cochrane Methodology
Register (September 2012), Health Technology Assessment
(September 2012), NHS Economic Evaluation Database (Septem-
ber 2012). The databases in Chinese included CNKI (China
Knowledge Resource Integrated Database, China academic
journals, conference proceedings and theses; 1979 to September
2012).
Inclusion Criteria
Studies included in the meta-analysis had to meet all of the
following criteria: (1) Participants: NSCLC patients had to be
diagnosed by pathological sections and were treated by the CT. (2)
Type of studies: only clinical randomized controlled trials (RCTs)
were eligible. (3) Type of intervention: studies reported CT
combined with or without CHM. For studies using other agents as
the third arm, only the two arms using CHM and/or CT will be
included for analysis. (4) Type of outcome measurements: overall
survival rate and tumor response were the main outcome
measurements; other outcome measurement included reduction
in AEs of CT, improvement in clinical symptoms and blood
disorders were also considered.
Exclusion Criteria
Clinical trials were excluded if they did not meet the above
criteria. In addition, studies with the followings were also
excluded: (1) CHM were used in both of the intervention group
and control group; (2) Non-original research (e.g. review article,
letter to the editor); (3) Duplicated publications.
Outcome Measures
Survival rate, tumor response of CHM on the number of
patients with complete response (CR) or partial response (PR), as
well as those with progressive disease (PD) based on the WHO
scale were examined. The improved or stable performance status
of patients were investigated based on the Karnofsky performance
score (KPS), in which 100 refers to a normal subject with no
complaints, 70 refers to a patient unable to carry on normal
activity, 50 refers to a patient who requires considerable assistance,
40 refers to a disabled patient and 30 refers to a hospitalization-
recommended patient. The efficacy of CHM on relieving the AEs
of CT including nausea and vomiting, hemoglobin (HB), platelet
(PLT) were studied by grading the acute and subacute AEs of
cancer treatment.
Quality Assessment
Methodological quality of RCTs was assessed using the five-
point Jadad scale [9]. All trials were reviewed by at least two
reviewers and any disagreement was resolved by third reviewer
consensus. In addition, the risk of bias for the included studies was
also assessed.
Data Analysis
The Review Manager 5.1 software (Nordic Cochrane Centre,
Copenhagen, Denmark) was employed for data analysis. The
effect data is expressed as relative risk (RR) with 95% confidence
interval (CI). If the heterogeneity exists in pooled studies
(I2.50%), a random model was applied, otherwise the fix model
was applied. Statistic significant difference was considered as
p,0.05.
Results
Characteristics of the Included Studies
In the study, 2,998 articles were retrieved. 30 studies were
finally included. Among these studies, six studies were not pooled
for analysis as four studies had Jadad score 2 [10–13], and other
two studies did not report tumor-node-metastasis (TNM) staging
information [14,15]. Therefore, 24 eligible studies were included
for meta-analysis. The study selection process details were
described in Figure 1. A sum of 2,109 patients was enrolled in
these studies, at which 1,064 patients participated in CT combined
CHM (CTC) and 1,039 in CT (six patients dropped out and were
not reported the group enrolled). A total 78 patients withdraw or
dropped out, 36 patients in CTC, 36 in CT and six patients in
groups not specified.
All the patients recruited in the 24 studies were at stage III to IV
of NSCLC TNM, and all of the studies were graded at least Jadad
score 3. The risk of bias of all studies was shown in Table S1. The
course of treatment varied from 4 to 16 weeks in the included
studies. A list of therapeutic approaches and outcome assessment
in each study, and the quality of studies assessed by five-point
Jadad scale was listed in Table 1. All studies had claimed the
baseline were comparable except one study [32] including age,
gender, histopathology or TNM stage as shown in Table S2.
Survival
One-year survival was analyzed as shown in Figure 2. One-year
survival in pooled studies showed a significant rise in CTC
compared to CT alone (RR=1.36, 95% CI=1.15–1.60,
p = 0.0003, seven studies, 608 patients), with low heterogeneity
(I2 = 0%) [16–22]. A half-year survival also demonstrated a favor
of CTC compared to CT alone (RR=1.18, 95% CI= 1.04–1.33,
p = 0.008, two studies, 157 patients) as shown in Figure S1.
Immediate Tumor Response
As shown in Figure 3, CTC therapy was associated with a
significant increase in the number of patients who reported
complete or partial response (RR=1.36, 95% CI= 1.19–1.56,
Figure 5. Reduction of adverse effects. Reduction of adverse effects estimated from meta-analysis of pairwise comparisons in patients with
Chinese herbal medicine (CHM, treatment group) versus patients without CHM (control group). (A) Number of patients with nausea and vomiting at
toxicity grade of III-IV. (B) Number of patients with hemoglobin decline at the toxicity grade of I-IV with CTC therapy. (C) Number of patients with
hemoglobin decline at the toxicity grade III–IV with CTC therapy.
doi:10.1371/journal.pone.0057604.g005
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p,1.0E25, 18 studies, 1,623 patients) [16,18–34]. In addition, the
advantage of CTC therapy was found in the number of patients
who reported complete, partial and stable response (RR=1.14,
95% CI= 1.08–1.19, p,1.0E-5, 19 studies, 1,697 patients, figure
not showed).
Performance Status
Two types of KPS data were reported in the studies, the
improvement of KPS (ten-point cutoff) and the value of KPS in
pre- and post-treatment. Six studies of the 24 studies, with
evaluation of 526 patients were being analyzed. 35.1% and 10.9%
of patients reported improved (the increase of KPS$10) in CTC
(n= 270) and in CT (n= 256), respectively. Significant findings
with improvement were shown in the CTC (RR=2.90, 95%
CI= 1.62–5.18, p = 0.0003, six studies, 526 patients) (Figure 4)
[21,26,29,30,35,36]. There was no significant heterogeneity
among these studies (I2 = 51%). Dropping one of any studies did
not alter the result that favor of CTC. The value of KPS was
reported with pre-treatment in seven studies [19,24–26,30,34,37]
and post-treatment in four studies [24,25,34,37]. The pooled
studies showed that the KPS of pre-treatment had no significant
difference in CTC and CT (SMD=20.04, 95% CI=20.20-0.12,
p = 0.64, I2 = 0%). However, the pooled studies indicated the
heterogeneity in the four studies of post-treatment (SMD=1.03,
95% CI=20.09–2.14, p = 0.07, I2 = 95%). Interestingly, these
four studies all claimed significant improvement in CTC
compared to CT.
Reduction in CT Toxicity
Nausea and vomiting are common AEs of CT. A significant
reduction of nausea and vomiting at toxicity grade of III–IV in
CTC compared to CT therapy was found (RR=0.24, 95%
CI= 0.12–0.50, p= 1.0E24, five studies, 350 patients)
[19,24,25,30,31] (Figure 5A). However, there was significant
heterogeneity in the studies with reduction of nausea and vomiting
at toxicity grade of I–IV (data not shown). One study reported a
significant reduction of nausea and vomiting in CTC compared to
CT at the 10th day of second treatment, based on the
questionnaire EORTC QLQ-LC43 (combination of EORTC
QLQ-C30 and QLQ-LC13) [38]. The study was not pooled due
to the different data types.
The decrease of HB at the toxicity grade of I–IV in patients
with CTC therapy was significant reduced (RR=0.64, 95%
CI= 0.51–0.80, p,1.0E24, six studies, 553 patients, Figure 5B)
[19,24,29,30,34,39]; yet CTC therapy did not show a significant
difference in the decline of HB at the toxicity grade of III–IV
(RR=0.58, 95% CI= 0.26–1.29, p = 0.18, seven studies, 616
patients) compared to CT alone (Figure 5C)
[19,24,29,30,34,36,39].
The inhibition of white blood cells (WBCs) at the toxicity grade
of III–IV or I–IV in patients with CTC therapy was significant
reduced (RR=0.36, 95% CI= 0.26–0.52, p,1.0E25, nine
studies, 666 patients; RR=0.75, 95% CI= 0.67–0.84,
p,1.0E25, eight studies, 603 patients, respectively) (Figure 6A
and Figure 6B) [19,24,25,27,29–31,36,39].
The decrease of PLTs in numbers at the toxicity grade of III–IV
was significant prevented in patients with CTC therapy
(RR=0.34, 95% CI= 0.17–0.68, p = 0.002, seven studies, 557
patients) [19,24,25,29,34,36,39]. The decrease of PLTs in
numbers at the toxicity grade of III–IV was significant dismissed
in patients with CTC therapy (RR=0.43, 95% CI= 0.31–0.60,
p,1E25, six studies, 494 patients) [19,24,25,29,34,39]. In
addition, our study showed CTC therapy significantly prevented
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the decline of PLTs at the toxicity grade of III–IV and I–IV when
dropped any one study.
Herbs Frequently used in NSCLC
19 studies have reported herbs and decoctions. Among them,
Radix Astragalus, Radix Adenophorae and Radix Ophiopogonis are the
most commonly used herbs for NSCLC (Table 2).
Discussion
Recent studies showed that the use of CAM has increasingly
gained recognition and usage in cancer patients [40,41]. CHM is
especially popular among the CAM usage as palliative care for
cancer patients, but the efficacy of the combined use of CAM and
CT on advanced NSCLC cancer remains under explored due to
language barrier of many studies reported in Chinese language
[42]. Meta-analysis is a powerful statistical analysis of results from
individual studies, which increases the precision of a treatment
effect and settles controversies studies [43]. In the present study,
the pooled data with advanced NSCLC has shown that combined
therapy significantly improved the survival rates, immediate tumor
response and performance status of advanced NSCLC patients.
We also found that, when compared with CT alone, the CTC
therapy significantly reduce AEs associated with chemotherapeutic
interventions, including nausea and vomiting, decrease in the
peripheral blood leukocytes and HB (Figure 5 and Figure 6).
In contrast to most of the previous meta-analyses in this area,
our systematic review set the inclusion criteria with Jadad score
$3 to increase the study quality and included studies with stage
III–IV of TNM to minimize the heterogeneity among the studies.
It is also encouraging to see that the adjunctive use of CHM with
CT may prolong survival in advanced stage NSCLC patients, and
CT-related side effects appear to be less frequent and milder in the
use of concomitant CAM treatment, which suggest CAM may
enhance the compliance to CT and eventually result in improving
KPS of patients. The efficacy of CHM as an adjuvant therapy for
NSCLC is in line with our previous findings in colorectal cancer,
hepatocellular carcinoma and nasopharyngeal carcinoma [44–46].
According to Chinese medicine theory, illness is caused by the
disharmony of yin and yang, and Chinese medicine aims to restore
the balance of yin and yang to alleviate the disease symptoms.
CHMs have been commonly used in Asia for thousands of years.
Interestingly, it is reported that 61 out of 74 lung cancer patients
recruited by 17 Community Clinical Oncology Program (CCOP)
affiliates throughout the United States have used CAM while
undergoing CT or radiation therapy [47]. However, the potential
for integrating CAM into conventional CT treatment remains to
be evaluated [48]. Radix Astragalus, Radix Adenophorae, Radix
Ophiopogonis, Radix Glycyrrhizae, Poria and Oldenlandia diffusa identified
in the study have the function of tonifying qi, nourishing yin and
removing blood stasis, which are in accordance to the commonest
symptoms in NSCLC patients undergoing CT (i.e. blood stasis,
vital energy and yin deficiency). It is in line with other findings that
Radix Astragalus, Radix Ophiopogonis and Oldenlandia diffusa are
commonly used for NSCLC [49]. Besides, it has also been
reported that there was a significant effectiveness of adding
astragalus-based herbal treatment to standard CT regimens [50].
Several experimental researches have revealed that Adenophora
Polysaccharides and Oldenlandia diffusa extract could effectively
inhibited the growth of cancer cell lines and induced significant
increase of apoptosis. Furthermore, there was a significant
inhibition of lung metastases in animal model with no noticeable
AEs [51,52]. Radix Adenophorae and Radix Ophiopogonis were also
shown to have anti-inflammation and immunomodulating effects
[53,54]. Our previous studies have demonstrated that Radix
Astragalus, the dried root of Astragalus membranaceus, has anti-tumor,
immunomodulating and immunorestorative effects in vivo and in
vitro [55,56]. It is in accordance with other findings that Radix
Astragulus has immunologic benefits by stimulating macrophage,
natural killer cell activity but inhibiting T-helper cell type 2
cytokines [57]. In addition, the combination of Radix Astragulus and
Radix Angelicae increased WBC, HB and PLT in cyclophospha-
mide-induced anemic rat [58]. This study also indicated that these
two herbs are associated with enhancing erythropoietin expression
[58]. Erythropoietin is also able to prevent against cisplatin
cytotoxicity in cells via several mechanisms [59,60]. These findings
may give some insights on the mechanism of how CHM improved
the hematological parameters in this systematic review. Further-
more, Radix Astragalus also reduced toxicity induced by cyclophos-
phamide [61]. Though the molecular mechanism is not fully
understood, the immunostimulating effects and the reduction of
chemotherapy-induced toxicity may be the two major advantages
for CHM as adjuvant therapy in NSCLC treatment.
Survival rate, immediate tumor response and chemo-toxicity
are three major outcomes in the studies. However, not all the
studies simultaneously reported the three outcomes. For example,
Zhang et al. [21] reported all three outcomes while Li and Li [39]
reported the reduction of chemo-toxicity only. Nevertheless, we
analyzed all available data in these reports without any subjective
selection. KPS is a scale for the evaluation of cancer patients. In
this study, we analyzed continuous data (average of KPS scores)
and discontinuous data (patient number with an increase of
KPS$10). There is significant heterogeneity when we pooled
studies with continuous data, although the baseline has no
heterogeneity in the meta-analysis. The variation of KPS value
in the studies may be due to the differences in treatment duration,
Figure 6. Reduction of adverse effects. Reduction of adverse effects estimated from meta-analysis of pairwise comparisons in patients with
Chinese herbal medicine (CHM, treatment group) versus patients without CHM (control group). (A) The inhibition of white blood cells (WBCs) at the
toxicity grade of III–IV. (B) The inhibition of WBCs at the toxicity grade of I–IV. (C) The decrease of platelets in numbers at the toxicity grade of III–IV.
(D) The decrease of platelets in numbers at the toxicity grade of I–IV.
doi:10.1371/journal.pone.0057604.g006
Table 2. Herbs frequently used for non-small cell lung cancer.
Chinese herbal medicine Frequency
Count %
Radix Astragalus 10 52.6
Radix Adenophorae 8 42.1
Radix Ophiopogonis 7 36.8
Radix Glycyrrhizae 5 26.3
Poria 5 26.3
Herba Oldenlandia Diffusa 5 26.3
Radix Asparagi 4 21.1
Semen Persicae 4 21.1
Radix Notoginseng 4 21.1
doi:10.1371/journal.pone.0057604.t002
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treatment methods and the herb prescriptions in different studies.
Therefore, the change of KPS in patients is more accurate to
indicate the efficacy of treatments in pooled studies. The interval
of ten in KPS normally shows a significant change of performance
status as described by previous publications [26,57,62,63]. Hence,
we adopted a ten-point increase as the cutoff for improved
performance status. The findings showed a significant improve-
ment in KPS with CTC treatment.
In conclusion, the evidence from the meta-analysis of the
included studies shows that CHM as adjuvant therapy has
advantages in NSCLC patients. However, due to the complex
nature of CHM interventions, particular attention should be paid
to apply appropriate and rigorous research methodologies to
investigate CHM as a holistic system [64]. Therefore a large scale
RCT integrated the Chinese Medicine methodology of pattern
diagnosis and treatment is warranted for further study.
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